Cargando…

Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials

BACKGROUND & AIMS: Combined therapy inhibiting EGFR and VEGF pathways is becoming a promising therapy in the treatment of advanced non-small-cell lung cancer (NSCLC), however, with controversy. The study aims to compare the efficacy of combined inhibition therapy versus control therapy (includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yongzhao, Wang, Huixian, Shi, Yan, Cai, Shangli, Wu, Tongwei, Yan, Guangyue, Cheng, Sijin, Cui, Kang, Xi, Ying, Qi, Xiaolong, Zhang, Jie, Ma, Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351687/ https://www.ncbi.nlm.nih.gov/pubmed/27690345 http://dx.doi.org/10.18632/oncotarget.12294

Ejemplares similares

Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis
por: Chen, Shubo, et al.
Publicado: (2017)

Prognostic role of platelet to lymphocyte ratio in hepatocellular carcinoma: a systematic review and meta-analysis
por: Zhao, Yongzhao, et al.
Publicado: (2017)

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
por: Bian, Dongliang, et al.
Publicado: (2023)

VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in serum plus EGFR in tissue of patients with triple-negative breast cancer
por: Iosifidou, R, et al.
Publicado: (2009)

Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review)
por: Wang, Qian, et al.
Publicado: (2023)

Should patient enrollment criteria for anti‐VEGF phase III trials be reconsidered
por: Hanhart, Joel, et al.
Publicado: (2023)

Prognostic role of podocalyxin-like protein expression in various cancers: A systematic review and meta-analysis
por: Wang, Jing, et al.
Publicado: (2016)

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
por: Dong, Xinyue, et al.
Publicado: (2023)

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
por: Wang, Yaning, et al.
Publicado: (2021)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial
por: Yang, Lu, et al.
Publicado: (2018)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials
por: Mawalla, Brian, et al.
Publicado: (2018)

EGFR, VEGF, and angiogenesis promote the development of lipoma in the oral cavity
por: da Silva, Weslay Rodrigues, et al.
Publicado: (2023)

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Chau, Nicole G, et al.
Publicado: (2011)

The correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancer
por: Liu, Xiguang, et al.
Publicado: (2014)

Simultaneous EGFR and VEGF Alterations in Non-Small Cell Lung Carcinoma Based on Tissue Microarrays
por: Tsiambas, Evangelos, et al.
Publicado: (2007)

CAV2 promotes the growth of renal cell carcinoma through the EGFR/PI3K/Akt pathway
por: Liu, Fu, et al.
Publicado: (2018)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Prognostic and clinicopathological value of SIRT3 expression in various cancers: a systematic review and meta-analysis
por: Zhou, Yongping, et al.
Publicado: (2018)

Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised, controlled trial
por: Zhu, Feng‐Cai, et al.
Publicado: (2019)

Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Patients with/without EGFR-Mutation: Evidence Based on Recent Phase III Randomized Trials
por: Zhang, Wen-Qian, et al.
Publicado: (2014)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Laparoscopic Radiofrequency Fibroid Ablation: Phase II and Phase III Results
por: Galen, Donald I., et al.
Publicado: (2014)

Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis
por: Wang, Jichang, et al.
Publicado: (2015)

Will EGFRvIII and neuronal-derived EGFR be targets for imipramine?
por: Li, Zesheng, et al.
Publicado: (2023)

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes
por: Liu, Si-Yang, et al.
Publicado: (2021)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
por: ZHU, Lucheng, et al.
Publicado: (2021)

Id-1: Regulator of EGFR and VEGF and potential target for colorectal cancer therapy
por: Meteoglu, Ibrahim, et al.
Publicado: (2008)

Simultaneous Detection of EGFR and VEGF in Colorectal Cancer using Fluorescence-Raman Endoscopy
por: Kim, Yong-il, et al.
Publicado: (2017)

Knockdown of METTL16 disrupts learning and memory by reducing the stability of MAT2A mRNA
por: Zhang, Runjiao, et al.
Publicado: (2022)

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
por: Zhou, Qing, et al.
Publicado: (2022)

Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
por: Daud, Adil, et al.
Publicado: (2017)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

Triple Inhibition of EGFR, Met, and VEGF Suppresses Regrowth of HGF-Triggered, Erlotinib-Resistant Lung Cancer Harboring an EGFR Mutation
por: Nakade, Junya, et al.
Publicado: (2014)

First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
por: Hafner, Susanne
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9gg00em29923qmoqu0nnv0qrft